Valesca Bukur
Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Valesca Bukur works in Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cancer Genomics and Diagnostics, Breast Cancer Treatment Studies, Glioma Diagnosis and Treatment. Recorded institutional associations include Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
2017 · 2,473 citationsActively personalized vaccination trial for newly diagnosed glioblastoma
2018 · 935 citationsImproving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening
2018 · 362 citationsMulti-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
2020 · 210 citationsResponsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models
2018 · 193 citationsOXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation
2020 · 141 citationsNFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells
2016 · 72 citationsNF‐κB factors control the induction of NFATc1 in B lymphocytes
2014 · 17 citationsIVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
2017 · 15 citationsPublisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
2019 · 15 citationsAbstract OT2-06-01: Highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancer
2019 · 10 citationsTF-FVIIa PAR2-β-Arrestin Signaling Sustains Organ Dysfunction in Coxsackievirus B3 Infection of Mice
2024 · 8 citationsComprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient
2021 · 6 citationsAbstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial
2016 · 5 citationsAbstract CT202: IVAC MUTANOME: Individualized vaccines for the treatment of cancer
2015 · 4 citationsMutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
2018 · 4 citationsAbstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
2019 · 3 citationsTemporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma
2024 · 3 citationsAbstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
2019 · 2 citationsMutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer
2017 · 2 citationsCorrection: Corrigendum: NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells
2016 · 1 citationsAbstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma
2016 · 1 citationsAbstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project
2015 · 1 citationsAbstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
2016 · 0 citationsPO-324 Detection of high-risk prostate cancer biomarkers by RNA sequencing and qPCR method
2018 · 0 citations
